http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 28 Aug 2026 16:30:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++Alzamend+Neuro%2C+Inc.++++++For%3A+Oct+19/26998495.html si-local-file:///var/storage/secattach/20260828/26998495.html http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++Alzamend+Neuro%2C+Inc.++++++For%3A+Oct+19/26998495.html Fri, 28 Aug 2026 16:30:00 -0400 ALZN O.50762730 http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++Alzamend+Neuro%2C+Inc.++++++For%3A+Oct+19/26998495.html si-local-file:///var/storage/secattach/20260828/26998495.html http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++Alzamend+Neuro%2C+Inc.++++++For%3A+Oct+19/26998495.html Fri, 28 Aug 2026 16:30:00 -0400 ALZN O.50762730 http://www.streetinsider.com/Equity+Offerings/Alzamend+Neuro+%28ALZN%29+files+for+98.4M+share+offering+by+selling+stockholders/26961883.html <p>Alzamend Neuro (NASDAQ: ALZN) filed for up to 98,388,305 share offering by selling stockholders.</p> http://www.streetinsider.com/Equity+Offerings/Alzamend+Neuro+%28ALZN%29+files+for+98.4M+share+offering+by+selling+stockholders/26961883.html Fri, 21 Aug 2026 16:35:44 -0400 ALZN http://www.streetinsider.com/Corporate+News/Alzamend+Neuro+%28ALZN%29+files+for+98.4M+share+offering+by+selling+stockholders/26961883.html <p>Alzamend Neuro (NASDAQ: ALZN) filed for up to 98,388,305 share offering by selling stockholders.</p> http://www.streetinsider.com/Corporate+News/Alzamend+Neuro+%28ALZN%29+files+for+98.4M+share+offering+by+selling+stockholders/26961883.html Fri, 21 Aug 2026 16:35:44 -0400 ALZN http://www.streetinsider.com/SEC+Filings/Form++S-1++++++++Alzamend+Neuro%2C+Inc.+++++++++++++++++/26961797.html si-local-file:///var/storage/secattach/20260821/26961797.html http://www.streetinsider.com/SEC+Filings/Form++S-1++++++++Alzamend+Neuro%2C+Inc.+++++++++++++++++/26961797.html Fri, 21 Aug 2026 16:30:00 -0400 ALZN O.50762730 http://www.streetinsider.com/SEC+Filings/Form++S-1++++++++Alzamend+Neuro%2C+Inc.+++++++++++++++++/26961797.html si-local-file:///var/storage/secattach/20260821/26961797.html http://www.streetinsider.com/SEC+Filings/Form++S-1++++++++Alzamend+Neuro%2C+Inc.+++++++++++++++++/26961797.html Fri, 21 Aug 2026 16:30:00 -0400 ALZN O.50762730 http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Alzamend+Neuro%2C+Inc.++++++For%3A+Jul+31++Filed+by%3A+Hyperscale+Data%2C+Inc./26957597.html si-local-file:///var/storage/secattach/20260820/26957597.html http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Alzamend+Neuro%2C+Inc.++++++For%3A+Jul+31++Filed+by%3A+Hyperscale+Data%2C+Inc./26957597.html Thu, 20 Aug 2026 21:18:00 -0400 ALZN O.50762730 http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Alzamend+Neuro%2C+Inc.++++++For%3A+Jul+31++Filed+by%3A+Hyperscale+Data%2C+Inc./26957597.html si-local-file:///var/storage/secattach/20260820/26957597.html http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Alzamend+Neuro%2C+Inc.++++++For%3A+Jul+31++Filed+by%3A+Hyperscale+Data%2C+Inc./26957597.html Thu, 20 Aug 2026 21:18:00 -0400 ALZN O.50762730 http://www.streetinsider.com/SEC+Filings/Form++3A++++++++Alzamend+Neuro%2C+Inc.++++++For%3A+Jul+29++Filed+by%3A+Hyperscale+Data%2C+Inc./26957596.html si-local-file:///var/storage/secattach/20260820/26957596.html http://www.streetinsider.com/SEC+Filings/Form++3A++++++++Alzamend+Neuro%2C+Inc.++++++For%3A+Jul+29++Filed+by%3A+Hyperscale+Data%2C+Inc./26957596.html Thu, 20 Aug 2026 21:17:00 -0400 ALZN O.50762730 http://www.streetinsider.com/SEC+Filings/Form++3A++++++++Alzamend+Neuro%2C+Inc.++++++For%3A+Jul+29++Filed+by%3A+Hyperscale+Data%2C+Inc./26957596.html si-local-file:///var/storage/secattach/20260820/26957596.html http://www.streetinsider.com/SEC+Filings/Form++3A++++++++Alzamend+Neuro%2C+Inc.++++++For%3A+Jul+29++Filed+by%3A+Hyperscale+Data%2C+Inc./26957596.html Thu, 20 Aug 2026 21:17:00 -0400 ALZN O.50762730 http://www.streetinsider.com/FDA/Alzamend+Neuro+fMRI+data+accepted+for+neuroscience+conference+poster/26953177.html <p>Alzamend Neuro, Inc. (Nasdaq: ALZN) announced that an abstract reporting resting-state functional magnetic resonance imaging findings for its AL001 lithium compound has been accepted for poster presentation at Neuroscience 2026, the annual meeting of the Society for Neuroscience, to be held November 14–18, 2026, in Washington, DC.</p> <p>The presentation, titled "Assessing Treatment-Associated Brain Network Changes Following a Novel Lithium Treatment Using 7T Resting-State fMRI – Results from a Randomized Phase 1/2A Clinical Trial," is scheduled for November 18, 2026, from 8:00 a.m. to 12:00 p.m. in the Neuropsychiatric Disorders session.</p> <p>The poster will report findings from 7T resting-state fMRI evaluating treatment-associated changes http://www.streetinsider.com/FDA/Alzamend+Neuro+fMRI+data+accepted+for+neuroscience+conference+poster/26953177.html Thu, 20 Aug 2026 08:00:39 -0400 A.06822034 A.35954321 A.40221050 A.40718029 ALZN O.00071176 O.20026344 O.20042365 O.20737027 O.50762730 http://www.streetinsider.com/FDA/Alzamend+Neuro+fMRI+data+accepted+for+neuroscience+conference+poster/26953177.html <p>Alzamend Neuro, Inc. (Nasdaq: ALZN) announced that an abstract reporting resting-state functional magnetic resonance imaging findings for its AL001 lithium compound has been accepted for poster presentation at Neuroscience 2026, the annual meeting of the Society for Neuroscience, to be held November 14–18, 2026, in Washington, DC.</p> <p>The presentation, titled "Assessing Treatment-Associated Brain Network Changes Following a Novel Lithium Treatment Using 7T Resting-State fMRI – Results from a Randomized Phase 1/2A Clinical Trial," is scheduled for November 18, 2026, from 8:00 a.m. to 12:00 p.m. in the Neuropsychiatric Disorders session.</p> <p>The poster will report findings from 7T resting-state fMRI evaluating treatment-associated changes http://www.streetinsider.com/FDA/Alzamend+Neuro+fMRI+data+accepted+for+neuroscience+conference+poster/26953177.html Thu, 20 Aug 2026 08:00:39 -0400 A.06822034 A.35954321 A.40221050 A.40718029 ALZN O.00071176 O.20026344 O.20042365 O.20737027 O.50762730 http://www.streetinsider.com/FDA/Alzamend+Neuro+fMRI+data+accepted+for+neuroscience+conference+poster/26953177.html <p>Alzamend Neuro, Inc. (Nasdaq: ALZN) announced that an abstract reporting resting-state functional magnetic resonance imaging findings for its AL001 lithium compound has been accepted for poster presentation at Neuroscience 2026, the annual meeting of the Society for Neuroscience, to be held November 14–18, 2026, in Washington, DC.</p> <p>The presentation, titled "Assessing Treatment-Associated Brain Network Changes Following a Novel Lithium Treatment Using 7T Resting-State fMRI – Results from a Randomized Phase 1/2A Clinical Trial," is scheduled for November 18, 2026, from 8:00 a.m. to 12:00 p.m. in the Neuropsychiatric Disorders session.</p> <p>The poster will report findings from 7T resting-state fMRI evaluating treatment-associated changes http://www.streetinsider.com/FDA/Alzamend+Neuro+fMRI+data+accepted+for+neuroscience+conference+poster/26953177.html Thu, 20 Aug 2026 08:00:39 -0400 A.06822034 A.35954321 A.40221050 A.40718029 ALZN O.00071176 O.20026344 O.20042365 O.20737027 O.50762730 http://www.streetinsider.com/FDA/Alzamend+Neuro+fMRI+data+accepted+for+neuroscience+conference+poster/26953177.html <p>Alzamend Neuro, Inc. (Nasdaq: ALZN) announced that an abstract reporting resting-state functional magnetic resonance imaging findings for its AL001 lithium compound has been accepted for poster presentation at Neuroscience 2026, the annual meeting of the Society for Neuroscience, to be held November 14–18, 2026, in Washington, DC.</p> <p>The presentation, titled "Assessing Treatment-Associated Brain Network Changes Following a Novel Lithium Treatment Using 7T Resting-State fMRI – Results from a Randomized Phase 1/2A Clinical Trial," is scheduled for November 18, 2026, from 8:00 a.m. to 12:00 p.m. in the Neuropsychiatric Disorders session.</p> <p>The poster will report findings from 7T resting-state fMRI evaluating treatment-associated changes http://www.streetinsider.com/FDA/Alzamend+Neuro+fMRI+data+accepted+for+neuroscience+conference+poster/26953177.html Thu, 20 Aug 2026 08:00:39 -0400 A.06822034 A.35954321 A.40221050 A.40718029 ALZN O.00071176 O.20026344 O.20042365 O.20737027 O.50762730 http://www.streetinsider.com/FDA/Alzamend+Neuro+fMRI+data+accepted+for+neuroscience+conference+poster/26953177.html <p>Alzamend Neuro, Inc. (Nasdaq: ALZN) announced that an abstract reporting resting-state functional magnetic resonance imaging findings for its AL001 lithium compound has been accepted for poster presentation at Neuroscience 2026, the annual meeting of the Society for Neuroscience, to be held November 14–18, 2026, in Washington, DC.</p> <p>The presentation, titled "Assessing Treatment-Associated Brain Network Changes Following a Novel Lithium Treatment Using 7T Resting-State fMRI – Results from a Randomized Phase 1/2A Clinical Trial," is scheduled for November 18, 2026, from 8:00 a.m. to 12:00 p.m. in the Neuropsychiatric Disorders session.</p> <p>The poster will report findings from 7T resting-state fMRI evaluating treatment-associated changes http://www.streetinsider.com/FDA/Alzamend+Neuro+fMRI+data+accepted+for+neuroscience+conference+poster/26953177.html Thu, 20 Aug 2026 08:00:39 -0400 A.06822034 A.35954321 A.40221050 A.40718029 ALZN O.00071176 O.20026344 O.20042365 O.20737027 O.50762730 http://www.streetinsider.com/FDA/Alzamend+Neuro+fMRI+data+accepted+for+neuroscience+conference+poster/26953177.html <p>Alzamend Neuro, Inc. (Nasdaq: ALZN) announced that an abstract reporting resting-state functional magnetic resonance imaging findings for its AL001 lithium compound has been accepted for poster presentation at Neuroscience 2026, the annual meeting of the Society for Neuroscience, to be held November 14–18, 2026, in Washington, DC.</p> <p>The presentation, titled "Assessing Treatment-Associated Brain Network Changes Following a Novel Lithium Treatment Using 7T Resting-State fMRI – Results from a Randomized Phase 1/2A Clinical Trial," is scheduled for November 18, 2026, from 8:00 a.m. to 12:00 p.m. in the Neuropsychiatric Disorders session.</p> <p>The poster will report findings from 7T resting-state fMRI evaluating treatment-associated changes http://www.streetinsider.com/FDA/Alzamend+Neuro+fMRI+data+accepted+for+neuroscience+conference+poster/26953177.html Thu, 20 Aug 2026 08:00:39 -0400 A.06822034 A.35954321 A.40221050 A.40718029 ALZN O.00071176 O.20026344 O.20042365 O.20737027 O.50762730 http://www.streetinsider.com/FDA/Alzamend+Neuro+fMRI+data+accepted+for+neuroscience+conference+poster/26953177.html <p>Alzamend Neuro, Inc. (Nasdaq: ALZN) announced that an abstract reporting resting-state functional magnetic resonance imaging findings for its AL001 lithium compound has been accepted for poster presentation at Neuroscience 2026, the annual meeting of the Society for Neuroscience, to be held November 14–18, 2026, in Washington, DC.</p> <p>The presentation, titled "Assessing Treatment-Associated Brain Network Changes Following a Novel Lithium Treatment Using 7T Resting-State fMRI – Results from a Randomized Phase 1/2A Clinical Trial," is scheduled for November 18, 2026, from 8:00 a.m. to 12:00 p.m. in the Neuropsychiatric Disorders session.</p> <p>The poster will report findings from 7T resting-state fMRI evaluating treatment-associated changes http://www.streetinsider.com/FDA/Alzamend+Neuro+fMRI+data+accepted+for+neuroscience+conference+poster/26953177.html Thu, 20 Aug 2026 08:00:39 -0400 A.06822034 A.35954321 A.40221050 A.40718029 ALZN O.00071176 O.20026344 O.20042365 O.20737027 O.50762730 http://www.streetinsider.com/FDA/Alzamend+Neuro+fMRI+data+accepted+for+neuroscience+conference+poster/26953177.html <p>Alzamend Neuro, Inc. (Nasdaq: ALZN) announced that an abstract reporting resting-state functional magnetic resonance imaging findings for its AL001 lithium compound has been accepted for poster presentation at Neuroscience 2026, the annual meeting of the Society for Neuroscience, to be held November 14–18, 2026, in Washington, DC.</p> <p>The presentation, titled "Assessing Treatment-Associated Brain Network Changes Following a Novel Lithium Treatment Using 7T Resting-State fMRI – Results from a Randomized Phase 1/2A Clinical Trial," is scheduled for November 18, 2026, from 8:00 a.m. to 12:00 p.m. in the Neuropsychiatric Disorders session.</p> <p>The poster will report findings from 7T resting-state fMRI evaluating treatment-associated changes http://www.streetinsider.com/FDA/Alzamend+Neuro+fMRI+data+accepted+for+neuroscience+conference+poster/26953177.html Thu, 20 Aug 2026 08:00:39 -0400 A.06822034 A.35954321 A.40221050 A.40718029 ALZN O.00071176 O.20026344 O.20042365 O.20737027 O.50762730 http://www.streetinsider.com/FDA/Alzamend+Neuro+fMRI+data+accepted+for+neuroscience+conference+poster/26953177.html <p>Alzamend Neuro, Inc. (Nasdaq: ALZN) announced that an abstract reporting resting-state functional magnetic resonance imaging findings for its AL001 lithium compound has been accepted for poster presentation at Neuroscience 2026, the annual meeting of the Society for Neuroscience, to be held November 14–18, 2026, in Washington, DC.</p> <p>The presentation, titled "Assessing Treatment-Associated Brain Network Changes Following a Novel Lithium Treatment Using 7T Resting-State fMRI – Results from a Randomized Phase 1/2A Clinical Trial," is scheduled for November 18, 2026, from 8:00 a.m. to 12:00 p.m. in the Neuropsychiatric Disorders session.</p> <p>The poster will report findings from 7T resting-state fMRI evaluating treatment-associated changes http://www.streetinsider.com/FDA/Alzamend+Neuro+fMRI+data+accepted+for+neuroscience+conference+poster/26953177.html Thu, 20 Aug 2026 08:00:39 -0400 A.06822034 A.35954321 A.40221050 A.40718029 ALZN O.00071176 O.20026344 O.20042365 O.20737027 O.50762730 http://www.streetinsider.com/FDA/Alzamend+Neuro+fMRI+data+accepted+for+neuroscience+conference+poster/26953177.html <p>Alzamend Neuro, Inc. (Nasdaq: ALZN) announced that an abstract reporting resting-state functional magnetic resonance imaging findings for its AL001 lithium compound has been accepted for poster presentation at Neuroscience 2026, the annual meeting of the Society for Neuroscience, to be held November 14–18, 2026, in Washington, DC.</p> <p>The presentation, titled "Assessing Treatment-Associated Brain Network Changes Following a Novel Lithium Treatment Using 7T Resting-State fMRI – Results from a Randomized Phase 1/2A Clinical Trial," is scheduled for November 18, 2026, from 8:00 a.m. to 12:00 p.m. in the Neuropsychiatric Disorders session.</p> <p>The poster will report findings from 7T resting-state fMRI evaluating treatment-associated changes http://www.streetinsider.com/FDA/Alzamend+Neuro+fMRI+data+accepted+for+neuroscience+conference+poster/26953177.html Thu, 20 Aug 2026 08:00:39 -0400 A.06822034 A.35954321 A.40221050 A.40718029 ALZN O.00071176 O.20026344 O.20042365 O.20737027 O.50762730 http://www.streetinsider.com/Press+Releases/Alzamend+Neuro%27s+Phase+12A+Lithium+Neuroimaging+Data+Accepted+for+Poster+Presentation+at+Neuroscience+2026+in+Washington%2C+DC/26953129.html <div class="xn-content"> <ul type="disc"><li><b><i>Neuroscience 2026, the annual meeting of the <span value="ACORN:4071802978" idsrc="xmltag.org" >Society for Neuroscience</span>, will be held November 14–18, 2026</i></b> <b><i>in <location value="LU/us.dc.wash" idsrc="xmltag.org" >Washington, DC</location></i></b></li><li><b><i>Presentation Title: Assessing Treatment-Associated Brain Network Changes Following a Novel Lithium Treatment Using 7T Resting-State fMRI – Results from a Randomized Phase</i></b><b><i> 1/2A Clinical Trial</i></b></li></ul><p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4756462-1&amp;h=3602723169&amp;u=https%3A%2F%2Fwww.alzamend.com%2F&amp;a=Alzamend+Neuro%2C+Inc." target="_blank" rel="nofollow"><b><span value="NASDAQ-NMS:ALZN" idsrc="xmltag.org" >Alzamend Neuro, Inc.</span></b></a> (Nasdaq: ALZN) ("<b>Alzamend</b>"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("<b>Alzheimer's</b>"), bipolar disorder type 1 ("<b>BD</b>"), major depressive disorder ("<b>MDD</b>") and post-traumatic stress http://www.streetinsider.com/Press+Releases/Alzamend+Neuro%27s+Phase+12A+Lithium+Neuroimaging+Data+Accepted+for+Poster+Presentation+at+Neuroscience+2026+in+Washington%2C+DC/26953129.html Thu, 20 Aug 2026 08:00:00 -0400 A.06822034 A.35954321 A.40221050 A.40718029 ALZN O.00071176 O.20026344 O.20042365 O.20737027 O.50762730 http://www.streetinsider.com/Press+Releases/Alzamend+Neuro%27s+Phase+12A+Lithium+Neuroimaging+Data+Accepted+for+Poster+Presentation+at+Neuroscience+2026+in+Washington%2C+DC/26953129.html <div class="xn-content"> <ul type="disc"><li><b><i>Neuroscience 2026, the annual meeting of the <span value="ACORN:4071802978" idsrc="xmltag.org" >Society for Neuroscience</span>, will be held November 14–18, 2026</i></b> <b><i>in <location value="LU/us.dc.wash" idsrc="xmltag.org" >Washington, DC</location></i></b></li><li><b><i>Presentation Title: Assessing Treatment-Associated Brain Network Changes Following a Novel Lithium Treatment Using 7T Resting-State fMRI – Results from a Randomized Phase</i></b><b><i> 1/2A Clinical Trial</i></b></li></ul><p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4756462-1&amp;h=3602723169&amp;u=https%3A%2F%2Fwww.alzamend.com%2F&amp;a=Alzamend+Neuro%2C+Inc." target="_blank" rel="nofollow"><b><span value="NASDAQ-NMS:ALZN" idsrc="xmltag.org" >Alzamend Neuro, Inc.</span></b></a> (Nasdaq: ALZN) ("<b>Alzamend</b>"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("<b>Alzheimer's</b>"), bipolar disorder type 1 ("<b>BD</b>"), major depressive disorder ("<b>MDD</b>") and post-traumatic stress http://www.streetinsider.com/Press+Releases/Alzamend+Neuro%27s+Phase+12A+Lithium+Neuroimaging+Data+Accepted+for+Poster+Presentation+at+Neuroscience+2026+in+Washington%2C+DC/26953129.html Thu, 20 Aug 2026 08:00:00 -0400 A.06822034 A.35954321 A.40221050 A.40718029 ALZN O.00071176 O.20026344 O.20042365 O.20737027 O.50762730 http://www.streetinsider.com/Press+Releases/Alzamend+Neuro%27s+Phase+12A+Lithium+Neuroimaging+Data+Accepted+for+Poster+Presentation+at+Neuroscience+2026+in+Washington%2C+DC/26953129.html <div class="xn-content"> <ul type="disc"><li><b><i>Neuroscience 2026, the annual meeting of the <span value="ACORN:4071802978" idsrc="xmltag.org" >Society for Neuroscience</span>, will be held November 14–18, 2026</i></b> <b><i>in <location value="LU/us.dc.wash" idsrc="xmltag.org" >Washington, DC</location></i></b></li><li><b><i>Presentation Title: Assessing Treatment-Associated Brain Network Changes Following a Novel Lithium Treatment Using 7T Resting-State fMRI – Results from a Randomized Phase</i></b><b><i> 1/2A Clinical Trial</i></b></li></ul><p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4756462-1&amp;h=3602723169&amp;u=https%3A%2F%2Fwww.alzamend.com%2F&amp;a=Alzamend+Neuro%2C+Inc." target="_blank" rel="nofollow"><b><span value="NASDAQ-NMS:ALZN" idsrc="xmltag.org" >Alzamend Neuro, Inc.</span></b></a> (Nasdaq: ALZN) ("<b>Alzamend</b>"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("<b>Alzheimer's</b>"), bipolar disorder type 1 ("<b>BD</b>"), major depressive disorder ("<b>MDD</b>") and post-traumatic stress http://www.streetinsider.com/Press+Releases/Alzamend+Neuro%27s+Phase+12A+Lithium+Neuroimaging+Data+Accepted+for+Poster+Presentation+at+Neuroscience+2026+in+Washington%2C+DC/26953129.html Thu, 20 Aug 2026 08:00:00 -0400 A.06822034 A.35954321 A.40221050 A.40718029 ALZN O.00071176 O.20026344 O.20042365 O.20737027 O.50762730 http://www.streetinsider.com/Press+Releases/Alzamend+Neuro%27s+Phase+12A+Lithium+Neuroimaging+Data+Accepted+for+Poster+Presentation+at+Neuroscience+2026+in+Washington%2C+DC/26953129.html <div class="xn-content"> <ul type="disc"><li><b><i>Neuroscience 2026, the annual meeting of the <span value="ACORN:4071802978" idsrc="xmltag.org" >Society for Neuroscience</span>, will be held November 14–18, 2026</i></b> <b><i>in <location value="LU/us.dc.wash" idsrc="xmltag.org" >Washington, DC</location></i></b></li><li><b><i>Presentation Title: Assessing Treatment-Associated Brain Network Changes Following a Novel Lithium Treatment Using 7T Resting-State fMRI – Results from a Randomized Phase</i></b><b><i> 1/2A Clinical Trial</i></b></li></ul><p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4756462-1&amp;h=3602723169&amp;u=https%3A%2F%2Fwww.alzamend.com%2F&amp;a=Alzamend+Neuro%2C+Inc." target="_blank" rel="nofollow"><b><span value="NASDAQ-NMS:ALZN" idsrc="xmltag.org" >Alzamend Neuro, Inc.</span></b></a> (Nasdaq: ALZN) ("<b>Alzamend</b>"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("<b>Alzheimer's</b>"), bipolar disorder type 1 ("<b>BD</b>"), major depressive disorder ("<b>MDD</b>") and post-traumatic stress http://www.streetinsider.com/Press+Releases/Alzamend+Neuro%27s+Phase+12A+Lithium+Neuroimaging+Data+Accepted+for+Poster+Presentation+at+Neuroscience+2026+in+Washington%2C+DC/26953129.html Thu, 20 Aug 2026 08:00:00 -0400 A.06822034 A.35954321 A.40221050 A.40718029 ALZN O.00071176 O.20026344 O.20042365 O.20737027 O.50762730 http://www.streetinsider.com/Press+Releases/Alzamend+Neuro%27s+Phase+12A+Lithium+Neuroimaging+Data+Accepted+for+Poster+Presentation+at+Neuroscience+2026+in+Washington%2C+DC/26953129.html <div class="xn-content"> <ul type="disc"><li><b><i>Neuroscience 2026, the annual meeting of the <span value="ACORN:4071802978" idsrc="xmltag.org" >Society for Neuroscience</span>, will be held November 14–18, 2026</i></b> <b><i>in <location value="LU/us.dc.wash" idsrc="xmltag.org" >Washington, DC</location></i></b></li><li><b><i>Presentation Title: Assessing Treatment-Associated Brain Network Changes Following a Novel Lithium Treatment Using 7T Resting-State fMRI – Results from a Randomized Phase</i></b><b><i> 1/2A Clinical Trial</i></b></li></ul><p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>Aug. 20, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4756462-1&amp;h=3602723169&amp;u=https%3A%2F%2Fwww.alzamend.com%2F&amp;a=Alzamend+Neuro%2C+Inc." target="_blank" rel="nofollow"><b><span value="NASDAQ-NMS:ALZN" idsrc="xmltag.org" >Alzamend Neuro, Inc.</span></b></a> (Nasdaq: ALZN) ("<b>Alzamend</b>"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("<b>Alzheimer's</b>"), bipolar disorder type 1 ("<b>BD</b>"), major depressive disorder ("<b>MDD</b>") and post-traumatic stress http://www.streetinsider.com/Press+Releases/Alzamend+Neuro%27s+Phase+12A+Lithium+Neuroimaging+Data+Accepted+for+Poster+Presentation+at+Neuroscience+2026+in+Washington%2C+DC/26953129.html Thu, 20 Aug 2026 08:00:00 -0400 A.06822034 A.35954321 A.40221050 A.40718029 ALZN O.00071176 O.20026344 O.20042365 O.20737027 O.50762730